Invivyd formed the SPEAR Study Group to investigate the potential of monoclonal antibody therapy for Long COVID and Post-Vaccination Syndrome (PVS), conditions potentially linked to persistent SARS-CoV-2 virus or spike protein. The group, composed of leading experts in Long COVID and PVS, will design and conduct clinical trials evaluating Invivyd’s monoclonal antibody, pemivibart (PEMGARDA), currently authorized for pre-exposure prophylaxis of COVID-19 in immunocompromised individuals. The formation of this group follows anecdotal reports suggesting pemivibart may alleviate Long COVID symptoms.
This research is crucial because it addresses a significant unmet medical need. Millions of Americans experience Long COVID, a debilitating condition with no approved treatments. This initiative directly investigates a promising therapeutic avenue, offering hope for effective interventions and a better understanding of the underlying disease mechanisms. Specifically, exploring the role of persistent virus or spike protein in Long COVID and PVS could revolutionize how these conditions are diagnosed and treated.
The SPEAR Study Group will conduct rigorous, controlled assessments of monoclonal antibody safety, translational biology, and exploratory efficacy. The studies will focus on patients with persistent virus or circulating spike protein. Invivyd’s next-generation monoclonal antibody candidate, VYD2311, will also be included in the research. This structured approach, combined with the expertise of the SPEAR Study Group members, strengthens the potential for meaningful results and informs future registrational studies.
This research could be a turning point in the fight against Long COVID and PVS. Positive results could lead to the development of the first approved treatments for these conditions, significantly impacting the lives of millions. Furthermore, the insights gained from these studies could advance the understanding of Long COVID’s underlying biology, paving the way for more targeted and effective therapies in the future. This endeavor represents a significant investment in addressing the long-term consequences of COVID-19 and underscores the potential of monoclonal antibodies as a therapeutic strategy for chronic viral illnesses.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
